Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. Viatris beat analysts’ revenue expectations by 1% last quarter ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other large-cap stocks. The big and large-cap stocks have spearheaded the rally in the past two ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...

CANONSBURG, Pa. (AP) — CANONSBURG, Pa. (AP) — Viatris Inc (VTRS) on Thursday reported a loss of $516.5 million in its fourth quarter. The Canonsburg, Pennsylvania-based company said it had a ...

Viatris (NASDAQ:VTRS) is scheduled to announce Q4 earnings results on Thursday, February 27th, before market open. SA analyses from early this year have ranged from cautious to optimistic ...

I’m delighted to have the CEO of Viatris, Scott Smith; and Doretta Mistras, the CFO of Viatris. Scott, I know you’re not scheduled to come here originally and really delighted that you could ...

Viatris (VTRS) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago. These figures ...

With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate deal with Viatris.

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Viatris Inc. (VTRS) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript) 43rd Annual J.P. Morgan Healthcare Conference 2025 Viatris Non-GAAP EPS of $0.54 misses by $0.03, revenue of $3 ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...